Quoin Pharma gets FDA clearance for whole-body QRX003 study in Netherton Syndrome

Quoin Pharmaceuticals, Ltd.

FDA clearance for new Netherton Syndrome study of QRX003 applied to >80% BSA twice daily for 12 weeks in up to 8 patients.
Prior studies used ~20% BSA; new whole-body design mimics real-world use to support potential regulatory approval.
Study led by Dr. Amy Paller at Northwestern University; data to supplement QRX003 NDA package.
Quoin is a clinical-stage specialty pharma focused on rare/orphan diseases; stock trades as QNRX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.